drugset / Trial / NCT00353938

Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder

NCT00353938

RandomizedParallel-groupTriple-blindTreatment

Summary

This study will examine MDMA-assisted psychotherapy in individuals aged 18 years or older diagnosed with PTSD, with PTSD symptoms not improving after trying at least one treatment. This objective of this study is to determine whether three eight-hour long sessions of MDMA-assisted psychotherapy, scheduled three to five weeks apart, can be safely administered to participants with PTSD, and whether combining a fully therapeutic dose of MDMA with psychotherapy, when compared with a low ("active placebo") dose of MDMA, will reduce PTSD symptoms. Participants will be randomly assigned to receive the full dose of MDMA (125 mg) or assigned to receive a low or "active placebo" dose of MDMA (25 mg) during each of three experimental sessions.

Timeline

Start
2006-09-13
Primary completion
2009-09-02
Completion
2011-01-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Midomafetamine Unknown 25 mg Oral
Subject Midomafetamine Unknown 125 mg Oral